Anika Therapeutics Inc (ANIK)
Healthcare
Drug Manufacturers - Specialty & Generic
19.30 $
+6.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Anika Therapeutics Inc (ANIK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.2% of the shares are freely tradable; institutional investors hold 94.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
94.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
6.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
13Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 11.99 | 1,594,893 | -3.6 | 03/31/2026 |
| Caligan Partners LP | 10.79 | 1,435,130 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 6.55 | 872,066 | +12.9 | 03/31/2026 |
| Vanguard Group Inc | 5.86 | 779,165 | -0.2 | 12/31/2025 |
| Acadian Asset Management LLC | 4.56 | 606,544 | +35,143.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.55 | 605,777 | +0.0 | 03/31/2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 3.98 | 529,503 | -0.9 | 03/31/2026 |
| Renaissance Technologies Corp | 3.77 | 502,217 | -2.6 | 03/31/2026 |
| Dimensional Fund Advisors, Inc. | 3.45 | 458,847 | -7.2 | 03/31/2026 |
| Capital Management Corp | 3.36 | 447,721 | -10.5 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.